FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1535014461> ?p ?o ?g. }

• W1535014461 endingPage "1027" @default.
• W1535014461 startingPage "1018" @default.
• W1535014461 abstract "Abstract Objectives β-Elemene, a natural compound extracted from over 50 different Chinese medicinal herbs and plants, has been effective in the treatment of hyperplastic and proliferative disorders such as prostatic hypertrophy, hysteromyoma and neoplasms. Our previous studies have demonstrated that β-elemene exhibits strong inhibitory activity in ovarian cancer cells. The aim of the present study was to assess the effect of β-elemene on prostate cancer cells as well as other types of tumour cells and to determine whether the effect of β-elemene on prostate cancer cell death was mediated through the induction of apoptosis. Methods The MTT assay was used to evaluate the ability of β-elemene to inhibit cellular proliferation in cancer cells. Cellular apoptosis was assessed by annexin V binding, TUNEL and ELISA-based assays. Caspase activity was measured using a caspases assay kit. The protein levels of Bcl-2, caspases, cytochrome c and poly(ADP-ribose) polymerase (PARP) were analysed by Western blotting. Key findings Here, we showed that β-elemene had an antiproliferative effect on androgen-insensitive prostate carcinoma DU145 and PC-3 cells. Treatment with β-elemene also inhibited the growth of brain, breast, cervical, colon and lung carcinoma cells. The effect of β-elemene on cancer cells was dose dependent, with IC50 values ranging from 47 to 95 µg/ml (230–465 µm). TUNEL assay and flow cytometric analysis using annxin V/propidium iodide staining revealed that the percentage of apoptotic prostate cancer cells was increased by β-elemene in a dose- and time-dependent manner. Moreover, β-elemene exposure resulted in a decreased Bcl-2 protein level, increased cytochrome c release, and activated PARP and caspase-3, -7, -9, and -10 in prostate cancer cells. Conclusions Overall, these findings suggest that β-elemene exerts broad-spectrum antitumour activity against many types of solid carcinoma and supports a proposal of β-elemene as a new potentially therapeutic drug for castration-resistant prostate cancer and other solid tumours." @default.
• W1535014461 created "2016-06-24" @default.
• W1535014461 creator A5023730854 @default.
• W1535014461 creator A5035852304 @default.
• W1535014461 creator A5040309827 @default.
• W1535014461 creator A5063020531 @default.
• W1535014461 creator A5091135797 @default.
• W1535014461 date "2010-07-21" @default.
• W1535014461 modified "2023-10-17" @default.
• W1535014461 title "Antineoplastic effect of <i>β</i>-elemene on prostate cancer cells and other types of solid tumour cells" @default.
• W1535014461 cites W125541327 @default.
• W1535014461 cites W1471515974 @default.
• W1535014461 cites W1506642042 @default.
• W1535014461 cites W1528048211 @default.
• W1535014461 cites W1604468403 @default.
• W1535014461 cites W1745634660 @default.
• W1535014461 cites W1967357725 @default.
• W1535014461 cites W1975244003 @default.
• W1535014461 cites W1975707648 @default.
• W1535014461 cites W1978008638 @default.
• W1535014461 cites W1991740460 @default.
• W1535014461 cites W1991931599 @default.
• W1535014461 cites W1997879915 @default.
• W1535014461 cites W2000868041 @default.
• W1535014461 cites W2004877384 @default.
• W1535014461 cites W2007127627 @default.
• W1535014461 cites W2007144541 @default.
• W1535014461 cites W2014476883 @default.
• W1535014461 cites W2015456276 @default.
• W1535014461 cites W202356157 @default.
• W1535014461 cites W2027044194 @default.
• W1535014461 cites W2030735294 @default.
• W1535014461 cites W2035729495 @default.
• W1535014461 cites W2047100770 @default.
• W1535014461 cites W2057734107 @default.
• W1535014461 cites W2058507321 @default.
• W1535014461 cites W2061094889 @default.
• W1535014461 cites W2061497413 @default.
• W1535014461 cites W2064117760 @default.
• W1535014461 cites W2068692412 @default.
• W1535014461 cites W2069915122 @default.
• W1535014461 cites W2072098931 @default.
• W1535014461 cites W2078003307 @default.
• W1535014461 cites W2084780129 @default.
• W1535014461 cites W2089302797 @default.
• W1535014461 cites W2102892939 @default.
• W1535014461 cites W2113489470 @default.
• W1535014461 cites W2120939161 @default.
• W1535014461 cites W2123970190 @default.
• W1535014461 cites W2132411546 @default.
• W1535014461 cites W2138425596 @default.
• W1535014461 cites W2139677318 @default.
• W1535014461 cites W2141569270 @default.
• W1535014461 cites W2146778341 @default.
• W1535014461 cites W2157805786 @default.
• W1535014461 cites W2601961232 @default.
• W1535014461 cites W2610733940 @default.
• W1535014461 cites W4245361947 @default.
• W1535014461 doi "https://doi.org/10.1111/j.2042-7158.2010.01135.x" @default.
• W1535014461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20663036" @default.
• W1535014461 hasPublicationYear "2010" @default.
• W1535014461 type Work @default.
• W1535014461 sameAs 1535014461 @default.
• W1535014461 citedByCount "95" @default.
• W1535014461 countsByYear W15350144612012 @default.
• W1535014461 countsByYear W15350144612013 @default.
• W1535014461 countsByYear W15350144612014 @default.
• W1535014461 countsByYear W15350144612015 @default.
• W1535014461 countsByYear W15350144612016 @default.
• W1535014461 countsByYear W15350144612017 @default.
• W1535014461 countsByYear W15350144612018 @default.
• W1535014461 countsByYear W15350144612019 @default.
• W1535014461 countsByYear W15350144612020 @default.
• W1535014461 countsByYear W15350144612021 @default.
• W1535014461 countsByYear W15350144612022 @default.
• W1535014461 countsByYear W15350144612023 @default.
• W1535014461 crossrefType "journal-article" @default.
• W1535014461 hasAuthorship W1535014461A5023730854 @default.
• W1535014461 hasAuthorship W1535014461A5035852304 @default.
• W1535014461 hasAuthorship W1535014461A5040309827 @default.
• W1535014461 hasAuthorship W1535014461A5063020531 @default.
• W1535014461 hasAuthorship W1535014461A5091135797 @default.
• W1535014461 hasBestOaLocation W15350144611 @default.
• W1535014461 hasConcept C121608353 @default.
• W1535014461 hasConcept C126322002 @default.
• W1535014461 hasConcept C185592680 @default.
• W1535014461 hasConcept C190283241 @default.
• W1535014461 hasConcept C196795494 @default.
• W1535014461 hasConcept C2775934118 @default.
• W1535014461 hasConcept C2776235491 @default.
• W1535014461 hasConcept C2776438761 @default.
• W1535014461 hasConcept C2779723316 @default.
• W1535014461 hasConcept C2780192828 @default.
• W1535014461 hasConcept C2781340500 @default.
• W1535014461 hasConcept C31573885 @default.
• W1535014461 hasConcept C502942594 @default.
• W1535014461 hasConcept C55493867 @default.
• W1535014461 hasConcept C71924100 @default.

• next